Share Price:

APNASPENAspen Pharmacare Hldgs19629226 (1.16%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Marketing

Team Overview

Our Consumer and OTC brands encompass a wide range of trusted products classified in the self-medication sector of the market. For the Commercial Business, this is where our proud legacy lies, and we continue to strengthen our leadership in the market through robust and innovative marketing strategies across 148 Consumer and OTC brands.
 
The Prescription brands incorporate branded and post-patent products.
Aspen’s leading prescription brands treat allergic rhinitis, asthma, bacterial infections, chronic obstructive pulmonary disease, cough and colds, hypertension, chronic inflammatory skin diseases, epilepsy, constipation, gout, hypothyroidism, inflammation, mental health disorders, pain, urinary tract infection, and women’s reproductive health.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam id nisl in urna euismod pellentesque vitae vitae mauris. Suspendisse faucibus ex sed convallis dignissim.

Name, Group Marketing Head

Working At Aspen

We believe that doing business in a sustainable and responsible manner is integral to our purpose, our values and our philosophy “Healthcare. We Care”.


Our sustainability commitments are integrated into the Group’s strategic objectives and underpin the way we do business.

 

Our sustainability commitments are integrated into the Group’s strategic objectives and underpin the way we do business.

Innovation

We constantly search for better ways of doing things

Excellence

We strive to be the best we can be to deliver the highest standards

Commitment

We go the extra mile, seeking to exceed expectations

Teamwork

We optimise our performance by pulling together

Integrity

Our integrity is not negotiable

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.